Blood tests may spot hidden liver damage in diabetics
NCT ID NCT04232293
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked at whether two blood tests, eLIFT and FibroMeter, can accurately detect liver fibrosis (scarring) in people with type 2 diabetes. The researchers compared these blood tests to standard methods like FibroScan and liver biopsy. The goal is to find a simpler, less invasive way to screen for liver damage in this high-risk group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If these blood tests prove accurate, they could offer a simple, non-invasive way to screen for liver fibrosis in people with type 2 diabetes, reducing the need for liver biopsies.
What could go wrong
This is a completed diagnostic study, not a treatment trial. The blood tests may not be accurate enough to replace current methods, and results may not apply to all patient groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU d'Angers
Angers, 49100, France
-
CHU de Nantes
Nantes, 44093, France